Commerce Bank Makes New Investment in United Therapeutics Corporation $UTHR

Commerce Bank bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,447 shares of the biotechnology company’s stock, valued at approximately $784,000.

A number of other institutional investors have also modified their holdings of UTHR. BlackRock Inc. acquired a new stake in shares of United Therapeutics during the second quarter worth $2,868,735,000. Wellington Management Group LLP grew its position in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. Norges Bank acquired a new position in United Therapeutics in the 4th quarter valued at $293,418,000. Avoro Capital Advisors LLC increased its stake in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC raised its position in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $511.97, for a total transaction of $4,863,715.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $166,105,082.71. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 424,075 shares of company stock worth $227,683,710. 8.60% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on UTHR. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Bank of America reduced their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Stock Performance

United Therapeutics stock opened at $516.68 on Thursday. The company has a market cap of $22.16 billion, a P/E ratio of 18.49, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The business has a fifty day moving average of $531.06 and a two-hundred day moving average of $538.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $6.41 EPS. Sell-side analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.